


PRODUCT INFORMATION



GW 856553X

Item No. 13614

CAS Registry No.: 585543-15-3
Formal Name: 6-[5-[(cyclopropylamino)carbonyl]-3-fluoro-2-methylphenyl]-N-(2,2-dimethylpropyl)-3-pyridinecarboxamide
Synonyms: GSK-AHAB, Losmapimod, SB 856553
MF: C₂₂H₂₆FN₃O₂
FW: 383.5
Purity: ≥98%
UV/Vis.: λ_{max}: 233 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

GW 856553X is supplied as a crystalline solid. A stock solution may be made by dissolving the GW 856553X in the solvent of choice. GW 856553X is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide, which should be purged with an inert gas. The solubility of GW 856553X in these solvents is approximately 30 mg/ml.

GW 856553X is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, GW 856553X should first be dissolved in ethanol and then diluted with the aqueous buffer of choice. GW 856553X has a solubility of approximately 0.01 mg/ml in a 1:50 solution of ethanol:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

GW 856553X is a dual inhibitor of p38α and p38β MAPK (K_is = 0.0079 and 0.025 μM, respectively, in cell-free assays).¹ It is selective for p38α and p38β MAPK over p38γ and p38δ MAPK when used at a concentration of 10 μM. GW 856553X inhibits LPS-induced TNF-α production in isolated rat and human peripheral blood mononuclear cells (PBMCs; IC₅₀s = 0.6 and 0.13 μM, respectively). It decreases disease severity in a mouse model of collagen-induced arthritis when administered at doses ranging from 0.8 to 20 mg/kg.² GW 856553X (1.2 and 12 mg/kg) improves survival, normalizes blood pressure, and reduces increases in plasma levels of HDL, LDL, and triglycerides in spontaneously hypertensive stroke-prone rats fed a high-salt high-fat diet.¹

References

1. Willette, R.N., Eybye, M.E., Olzinski, A.R., *et al.* Differential effects of p38 mitogen-activated protein kinase and cyclooxygenase 2 inhibitors in a model of cardiovascular disease. *J. Pharmacol. Exp. Ther.* **330**(3), 964-970 (2009).
2. Triantaphyllopoulos, K., Madden, L., Rioja, I., *et al.* *In vitro* target validation and *in vivo* efficacy of p38 MAP kinase inhibition in established chronic collagen-induced arthritis model: A pre-clinical study. *Clin. Exp. Rheumatol.* **28**(2), 176-185 (2010).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 11/17/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD

ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM

WWW.CAYMANCHEM.COM